Arvinas ARVN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program-specific external expense by Product | ||||||
| ARV-102 | $5.5M-15.4% | $5.7M+3.6% | $5M+11.1% | $3.8M+124% | $6.5M+400% | |
| ARV-393 | $3.7M+42.3% | $3.4M+54.5% | $2.6M+52.9% | $2.5M+47.1% | $2.6M+117% | |
| ARV-806 | $6.5M+622% | $5.8M+383% | $5.1M+538% | $1.7M+750% | $900K+800% | |
| Bavdegalutamide (ARV-110) | $200K-81.8% | $400K-76.5% | $300K-88.9% | $900K-64.0% | $1.1M-31.3% | |
| Other programs | $2.6M+52.9% | $1.7M— | $300K— | $800K— | $1.7M+1,600% | |
| Vepdegestrant ARV-471 | $8.9M-63.1% | $9.3M-29.0% | $14.2M-27.6% | $15.1M-39.8% | $24.1M+26.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arvinas break its business down?
- Arvinas (ARVN) reports program-specific external expense by product across 6 parts — ARV-102, ARV-393, ARV-806, Bavdegalutamide (ARV-110) and Other programs. Each is extracted from the segment footnotes and tracked over time.
- Where does Arvinas's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arvinas's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
